Abstract

Sub-Saharan Africa faces an epidemic of diabetes. Visual loss from diabetic retinopathy (DR) is both preventable and treatable. This article reviews the epidemiology and clinical features of DR and current evidence-based interventions in three areas: primary prevention of retinopathy by optimum medical management, early detection of pre-symptomatic disease and management of established retinopathy to prevent or mitigate visual loss. There are significant challenges to DR care in resource poor environments. Appropriate provision of effective interventions by health services can reduce social and economic costs associated with patient care.

Introduction

International Diabetes Federation has estimated that the number of adults with diabetes in Africa will expand by 98%, from 12.1 million in 2010 to 23.9 million in 2030. Diabetes causes visual impairment through early-onset cataract and diabetic retinopathy (DR), a progressive disease of the retinal microvasculature. Cataract and DR are the second and sixth leading causes of global visual impairment, respectively. Both are included in the list of nine target diseases of Vision 2020, a joint programme of WHO and the International Agency for the Prevention of Blindness. The 2009 WHO Malawi national STEPwise approach to surveillance (STEPS) survey estimated a prevalence of diabetes of 5.6% in adults aged 25 to 64 years. 90% of these have type II diabetes. Without intervention visual impairment as a result of diabetes will increasingly impose social and economic burdens on communities in Malawi. Visual loss from diabetic retinopathy is both preventable and treatable. Medical management of diabetes, early detection of retinopathy and timely treatment all diminish the risk of visual loss.

Who is at risk of diabetic retinopathy?

Large cohort studies in Europe and the US have demonstrated that the greatest risk factor for development of DR is duration of diabetes. The Wisconsin Epidemiologic Study of Diabetic Retinopathy (WESDR) showed an increase in the prevalence of DR from 17% in those having had diabetes for less than 5 years to 97.5% in those 15 years and over. Proliferative retinopathy affected 1.2% in those having diabetes for less than 10 years, against 67% in those having it for 35 years or more. Two key studies, the Diabetes Control and Complications Trial (DCCT) (type I diabetes study) and the United Kingdom Prospective Diabetes Study (UKPDS) (type II diabetes study) demonstrated additional risk factors for the development and progression of DR: glycaemic control (measured by HbA1c level) and hypertension. The more recent Action to Control Cardiovascular Risk in Diabetes (ACCORD) and Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) studies have highlighted the role of blood lipid levels. The effect of variables which are important in the Southern African context such as HIV and a high burden of infection with malaria are, at present, unknown.

What retinal changes occur?

The retina is supplied by two circulatory systems: the uveal (choroidal) circulation and the retinal vasculature. Ischaemic retina produces growth factors including vascular endothelial growth factor (VEGF). The growth of abnormal new vessels is stimulated from the optic disc or retina. New vessels are prone to bleeding (vitreous haemorrhage) and the accompanying fibrosis leads to tractional retinal detachment; both sight-threatening manifestations of PDR. (Figure 3.)

Non-proliferative diabetic retinopathy

DR can be classified either non-proliferative (NPDR) or proliferative (PDR). Non-proliferative DR is characterised by microaneurysms, intraretinal haemorrhages, venous beading and intraretinal microvascular abnormalities (IRMA). (Figure 2). NPDR is usually asymptomatic but may progress to PDR.

Proliferative diabetic retinopathy

Ischaemic retina produces growth factors including vascular endothelial growth factor (VEGF). The growth of abnormal new vessels is stimulated from the optic disc or retina. New vessels are prone to bleeding (vitreous haemorrhage) and the accompanying fibrosis leads to tractional retinal detachment; both sight-threatening manifestations of PDR. (Figure 3.)
Diabetic Maculopathy

Retina which is oedematous or ischaemic loses function and this will reduce vision if the central retina or macular is involved. Diabetic maculopathy can be divided into two types: macular oedema and macular ischaemia which may co-exist. Macular oedema occurs due to breakdown of the inner blood-retina barrier. Fluid which accumulates within the retina distorts its architecture. Deposition of serum lipids, usually around the edges of areas of microvascular leakage, are seen as ‘exudates’ (Figure 4). Exudates act as surrogate markers of retinal thickening and oedema which can only be seen when the retina is viewed stereoscopically. Oedema is assessed clinically and using imaging technology (Figures 5 and 6). Ischaemic maculopathy occurs due to capillary loss within the macula, is diagnosed by fluorescein angiography and is, at present, untreated.

How can diabetic retinopathy be assessed?

DR remains asymptomatic until vision is affected but by this time the condition may be irreversible. Treatment is most likely to be effective when performed before progression to advanced disease. Slit-lamp examination by a trained ophthalmologist and retinal photography with grading of retinopathy by accredited graders can be considered the reference standards for disease detection. Examination with the direct ophthalmoscope is less sensitive and specific for DR.

Fluorescein angiography can also be used clinically to examine the circulation of the retina and choroid. This method involves injecting a fluorescent dye and photographing the posterior section of the eye using a specialised camera to obtain an angiogram. Hyperfluorescence angiograms are usually caused by leaking capillaries and abnormal vasculatures, including neovascularisation, with blocked capillaries being the main cause of hypofluorescence.

How is diabetic retinopathy managed?

Risk of visual loss from DR is reduced by interventions which fall into 3 categories: primary prevention of microvascular complications, early detection of retinopathy and effective treatment of established disease.

Primary prevention

Glycaemic control

Risk of microvascular complications of diabetes are reduced by optimum glycaemic control. After mean duration of follow-up 6.5 years the DCCT achieved a reduction in mean HbA1c from 9.1% to 7.3% with reduction in progression of retinopathy of 76%4. After a mean duration of follow-up of 10 years in the UKPDS reduction of HbA1c 7.9% to 7.0% was associated with a 25% risk reduction of microvascular complications8. Both DCCT and UKPDS demonstrated legacy effects. In the DCCT after ten years follow-up where the glycosylated haemoglobin levels had converged completely, the former intensive treatment group still had 24% reduction in progression of retinopathy and 59% reduction in proliferative retinopathy15. However, very tight glycaemic control was associated with increased mortality in the ACCORD study [11]. Current guidelines suggest target HbA1c between 6.5 – 7.0 %16, however a target HbA1c of < 7.0% for type I diabetics and < 7.5% for type II diabetics is more suitable. This is because lower blood glucose targets are associated with increased mortality due to some patients’ inability to tolerate hypoglycaemia as well as there being limited access to treatment for hypoglycaemic, diabetic patients in Malawi.

Control of hypertension

Blood pressure control plays an important role in prevention and management of diabetic retinopathy. The UKPDS compared the control of hypertension in type II diabetic patients. A ‘tightly controlled’ group were treated with either a beta blocker or ACE inhibitor aiming for a BP below 150/85 mmHg. A less tight BP control group aimed for a BP below 180/105 mmHg. Following 7 years the tight control group showed a 34% reduction in the rate of progression in DR, a 47% reduction in visual loss and had 35% less need of laser photocoagulation compared to the less tight group10. Specific therapies blocking the renin-angiotensin system may have additional benefits, particularly for mild retinopathy, but should be discontinued during pregnancy16.

Lipid lowering agents

Observational data from the Early Treatment of Diabetic Retinopathy Study (ETDRS) suggest that elevated total serum cholesterol levels are associated with an increased risk of visual loss in patients with diabetic retinopathy17. The possibility of an effect of statins was investigated in the Collaborative Atorvastatin Diabetes Study (CARDS) [18]. Results were encouraging but the effect appears to be small. The FIELD study assessed the effects of long term lipid-lowering therapy with fenofibrate on reducing the progression of DR and the need for laser treatment. It
found that fewer patients receiving fenofibrate required laser treatment (3.4%) than those in the control group (4.9%). Interestingly, benefits were not related to changes in lipid levels so the mechanism of drug action remains unclear.

The ACCORD randomised trial, investigated whether intensive glycaemic control, combination therapy for dyslipidaemia and intensive blood-pressure control, would limit DR progression in type II diabetes. The rate of DR at 4 years being 6.5% for the fenofibrate group and 10.2% for the placebo group. Moderate vision loss was seen in 23.7% and 24.5% of participants in the fenofibrate and placebo groups respectively. Currently, the recommended serum lipid levels for diabetic patients are: an optimal LDL cholesterol concentration of <100 mg/dl, optimal HDL cholesterol level of >45 mg/dl and desirable triglycerides levels of <150 mg/dl.

Other medical interventions

Glitazones are effective at lowering glycosylated haemoglobin but their use is limited due to adverse effects. These agents were associated in a large case series with 2.6 fold in macular oedema. Current advice is to withdraw pioglitazone when macula oedema has developed. The effects of protein kinase C activation and its inhibition on treating DR and diabetic macular oedema are currently being investigated. Two studies, using the protein kinase C β-inhibitor, Ruboxistaurin, have compared visual loss in diabetic macular oedema and DR with moderately encouraging results. Although smoking contributes to other complications of diabetes no clear association of smoking and retinopathy has been demonstrated. Counselling and treatment for smoking is cost effective in diabetes management and a lack of benefit for DR should not alter advice to patients to stop smoking.

Screening for diabetic retinopathy

Diabetic retinopathy meets the WHO criteria for a screening programme: an important public health issue; a recognised pre-symptomatic stage; an acceptable screening procedure and an effective treatment. At present persons with diabetes are advised to attend for retinal examination every 12 months. Systematic screening is shown to be cost-effective for eight years preserved compared with no screening in developed countries. Variation in age of onset of diabetes, glycaemic control, sensitivity of the screening test and compliance rates influence the cost-effectiveness of screening programmes. Optimum screening intervals have yet to be defined and research on targeted screening based on disease risk factors is on-going.

Currently there is no systematic screening programme for DR in Malawi. There have been scattered reports of successful attempts to screen patients attending diabetes clinics for DR in Africa including the ‘LEOPARD’ programme in Ethiopia (Paul Dodson personal communication). Mumba et al. in Tanzania attempted to develop a register of known patients with diabetes. Defining an eligible population is an essential component of a screening programme but is a challenge in resource poor settings. Digital photography with telemedicine links, as used by the English national screening programme, has the potential to deliver cost effective, accessible screening to rural and remote populations. Unfortunately fundus cameras remain prohibitively expensive. Development of lower cost solutions could radically alter the landscape for DR care in Africa; research into appropriate technologies is needed. Automated fundus photograph analysis is an exciting innovation which has the potential to reduce the cost of screening programmes.

Treatments for sight threatening retinopathy

Despite the fact that the majority of patients with retinopathy do not require treatment, regular eye checks are required to assess whether or not intervention is required to prevent sight deterioration. The development of sight threatening maculopathy, severe non-proliferative retinopathy or proliferative retinopathy necessitates referral to an ophthalmologist.

Laser photocoagulation

The effectiveness of laser photocoagulation at reducing the likelihood of visual impairment and blindness in patients with proliferative diabetic retinopathy (PDR) and macular edema is well established. Laser for PDR involves ablation of peripheral retina with 1 to 5 thousand spaced burns to reduce the amount of ischaemic retina and VEGF it produces. The Diabetic Retinopathy Study was a multi-centre randomised trial evaluating the use of scatter photocoagulation in reducing visual loss in PDR. PRP reduced visual loss by 50% compared to no treatment. Laser for diabetic macular oedema involves treatment directly to leaking microaneurysms, and gentle laser (up to 300 burns) to the macula, thought to stimulate cellular fluid pumps. Laser cannot treat vision lost due to ischemic maculopathy. The ETDRS compared laser photocoagulation with observation for diabetic macular oedema. A 3 year period, there was a reduction from 24% to 12% in moderate visual loss for the laser group. Following treatment, visual acuity improved in only 3% of those treated.

In Malawi laser treatment is now available in the public sector at Lions Sight First Eye Units at both Kamuzu Central Hospital, Lilongwe and Queen Elizabeth Central Hospital, Blantyre. In Blantyre dedicated referral clinics can be accessed by doctors and ophthalmic clinical officers. Annual training for ophthalmic clinical officers in recognition and referral of DR is run in conjunction with the QECH Department of Medicine.

Intravitreal steroids

Laser photocoagulation is insufficient alone to prevent visual loss in all cases of diabetic macular oedema. Intravitreal triamcinolone acetone (IVTA) has been investigated as a monotherapy and as an adjunct to laser. There is good evidence that IVTA monotherapy is inferior to laser treatment at 3 year follow-up. The Diabetic Retinopathy Clinical Research Network (DRCR.net) demonstrated that IVTA combined with laser is inferior to ranibizumab with immediate or deferred laser, except in patients who are pseudophakic. Flucinolone slow release intravitreal implant is effective in macular oedema. Intravitreal steroid preparations are associated with a high incidence of raised intra-ocular pressure and cataract.

Intravitreal anti-VEGF agents

Levels of vascular endothelial growth factor (VEGF) are elevated in the vitreous and retina in patients with DR and diabetic macular oedema. Recent evidence demonstrates better short-term outcomes than laser alone for intra-vitreal monoclonal antibody therapies targeting the VEGF molecule in diabetic maculopathy which has already reduced vision. The 2010 landmark DRCR.net study compared intravitreal...
ranibizumab with prompt macular laser photocoagulation, ranibizumab with deferred laser photocoagulation, IVTA with prompt laser, or a sham injection with prompt laser. At 2 years, invitrareal ranibizumab combined with either prompt or deferred laser, showed superior improvements in best corrected visual acuity compared with laser treatment alone. There was a gain of at least 15 ETDRS letters in around 30% of patients in each of the ranibizumab arms, 15% for the laser monotherapy group, and 21% for the triamcinolone group.

Anti-VEGF agents, which require multiple repeat injections, will be increasingly used in resource-rich countries although with a continued role for laser. At present these agents are prohibitively expensive for widespread use in resource-poor countries (approximately US$800 per injection for the drug alone). However off-label use of the systemic anti-VEGF, bevacizumab (US$~70 per injection), is used in some African tertiary centres on a paying patient basis, an approach supported by the ‘BOLT’ study.15

Surgical management of diabetic retinopathy
Vitreoretinal surgery has an important role in managing advanced disease to mitigate visual loss. The objectives of surgical removal of the vitreous (vitreectomy) include removal of vitreous opacity (commonly blood) and/or fibrovascular proliferation, relieving retinal traction, achieving retinal reattachment, and allowing completion of scatter laser photocoagulation. A large case series showed that sight threatening complications are rare and in approximately 90% of cases, vision is improved or stabilised16. Vitrectomy may also be beneficial in maculopathy in cases where traction from the vitreous contributes to fluid accumulation. Currently vitreoretinal surgery is not available in Malawi.

What are the specific challenges for Malawi?
The best evidence currently available suggests that, of patients attending diabetes clinics in Malawi, approximately 20% have sight threatening diabetic retinopathy (STDR) and 5% proliferative diabetic retinopathy17 (approximately 3 times and 5 times levels reported in recent European and American studies, respectively). The burden of diabetes and its complications is borne predominantly by the working age population18. A disease which reduces the economic activity of this group affects individual, household and national economies. Diabetes care must compete in the political spectrum with other financial and health care initiatives. It does not lend itself to vertical programmes favoured by donors. However political attention is turning to non communicable disease (NCD) as witnessed by the UN high level meeting on NCD prevention and control, Sept 201119. The challenges for effective management of diabetes in sub-Saharan Africa have been recently reviewed by our group20. Policy makers require evidence based guidance on resource allocation.

Conclusion
Visual loss from diabetic retinopathy is both preventable and treatable. Effective and consistent medical management reduces incidence and progression of retinopathy. Detection of early, pre-symptomatic disease allows timely treatment with laser photocoagulation to prevent visual loss. If vision is lost, treatment with vitreoretinal surgery or agents injected intra-ocularly may stabilise or improve vision. There are significant challenges to DR care in resource poor environments. However, the improved provision of effective, evidence-based interventions by health professionals involved with diabetes care can reduce the social and economic impact on patients.

References


